ARC’s comprehensive European Health Technology Assessments (HTA) Toolkit was produced to give information about how treatments are evaluated and approved for use in the various member state healthcare systems. The Toolkit guides patients and patient groups on how they can participate in the process to ensure that those treatments that are developed for their amyloidosis can be made available in their countries.
Patient Resources
ARC’s European Health Technology Assessments (HTA) Toolkit
Related Content
-
Understanding Genetics in Hereditary ATTR AmyloidosisLibrary, Patients
Get the latest Amyloidosis news and research from ARC.
Join our newsletter